concerto healthai

While it is common to hear that drug developers are in the early stages of integrating artificial intelligence with their drug research, discovery, and development efforts, one Bristol Myers Squibb (BMS) executive recently offered a more descriptive and no less accurate metaphor stretching back some 45 years. Greg Meyers, Bristol Myers Squibb executive vice president … Read more